Arcturus Therapeutics Holdings (ARCT) Peer Comparison

$15.82

$0.26 (1.67%)

As on 04-Sep-2026 16:00EDT

Market cap

$450 Mln

Revenue (TTM)

$24 Mln

P/E Ratio

--

P/B Ratio

2.6

Div. Yield

0 %

Edit

	Arcturus Therapeutics Holdings (ARCT)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Market cap ($ Mln)	450	16,504	17,747	14,622	12,501
Revenue ($ Mln)	24	2,782	1,054	2,436	1,284
Net Profit ($ Mln)	-93.28	491.50	755.85	860.62	-325.10
Net Margin (%)	-391.90	17.67	71.69	35.33	-25.32
RoE (%)	-48.36	110.09	--	42.98	-57.72
Price to Earnings	--	34.72	20.93	18.56	--
Price-To-Book	2.57	38.18	10.51	7.95	23.94

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Arcturus Therapeutics Holdings (ARCT)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Operating Revenue	23.80	2,782.29	1,054.37	2,435.92	1,283.94
Cost of Revenue	4.68	1,982.07	103.47	85.67	109.42
Gross Profit	64.20	760.62	588.53	2,236.43	902.26
Operating Expenses	122.95	216.81	841.45	1,378.74	1,497.13
Operating Profit (EBIT)	-103.14	583.40	109.45	971.51	-322.62
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-93.28	598.92	101.11	1,035.47	-325.10
Provision for Tax	-16.69	107.42	-654.74	174.84	0.00
Profit after Tax (Net Income)	-93.28	491.50	755.85	860.62	-325.10
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Arcturus Therapeutics Holdings (ARCT)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Shareholder's Funds	171.81	433.86	1,435.90	1,843.76	523.72
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	18.97	187.89	384.48	288.55	346.72
Current Liabilities	33.54	1,435.43	464.70	361.93	374.20
Total Liabilities	271.15	1,975.47	1,302.02	2,844.42	1,259.59

Assets ($ Mln)

	Arcturus Therapeutics Holdings (ARCT)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Non-Current Assets	27.15	1,006.90	895.24	1,243.41	45.47
Current Assets	197.16	1,050.29	1,389.84	1,250.82	1,199.18
Total Assets	271.15	1,975.47	1,302.02	2,844.42	1,259.59
Total Debt*	22.93	120.10	449.89	165.93	347.75
Net Current Assets	163.63	-385.14	925.52	888.90	824.98

Cashflow ($ Mln)

	Arcturus Therapeutics Holdings (ARCT)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Cash From Operating Activities	-74.27	713.22	51.77	884.27	-189.55
Cash Flow from Investing Activities	-0.23	-31.14	-8.15	350.44	32.32
Cash from Financing Activities	13.38	-860.39	34.89	-969.59	255.98
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Arcturus Therapeutics Holdings (ARCT)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
ROCE (%)	-25.87	53.56	-30.01	32.82	-31.49
ROE (%)	-48.36	110.09	163.18	42.98	-57.72
ROA (%)	-30.40	15.64	31.68	29.32	-22.97
EBIT Margin (%)	-257.27	21.13	5.73	31.04	-18.97
Net Margin (%)	-391.90	17.67	71.69	35.33	-25.32
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Arcturus Therapeutics Holdings (ARCT)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Revenue Growth (%)	-79.07	24.67	114.85	9.23	149.04
EBIT Growth (%)	-1.41	18.70	136.39	-3.99	9.16
Net Profit Growth (%)	-55.04	17.50	378.76	42.89	-15.32
EPS Growth (%)	-50.27	26.84	353.27	50.42	-0.64
Book Value Growth (%)	-29.03	164.02	816.12	-0.70	-42.66

Valuation Ratios

	Arcturus Therapeutics Holdings (ARCT)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Price / Earnings	-2.55	36.06	-59.76	15.79	-45.32
Price / Book Value	2.57	38.18	10.51	7.95	23.94
Dividend Yield (%)	0.00	0.00	0.00	0.00	0.00
EV/EBITDA	-2.94	27.00	230.43	13.21	-39.74
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Arcturus Therapeutics Holdings (ARCT)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Debt to Equity	0.00	0.00	0.27	0.00	0.65
Short term debt to equity ratio	0.02	0.00	0.05	0.00	0.00
Current Ratio	5.88	0.73	2.99	3.46	3.20
Quick Ratio	5.88	0.73	2.32	3.38	2.94
Interest Coverage	-7,309.22	--	1.62	--	-9.32

Operating Efficiency Ratios

	Arcturus Therapeutics Holdings (ARCT)	Medpace Holdings (MEDP)	Ascendis Pharma A/S - ADR	Exelixis (EXEL)	Madrigal Pharmaceuticals (MDGL)
Debtors to sales (%)	7.62	15.88	21.25	13.74	14.98
Asset Turnover	0.08	0.89	0.44	0.83	0.91
Receivable days	25.91	50.42	85.52	43.48	35.88
Inventory Days	--	--	1,056.70	96.17	354.23
Payable days	689.99	6.26	331.01	147.97	300.79
Cash Conversion Cycle	--	--	811.21	-8.32	89.33

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly